Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Australia / NCT07026175
Recruiting Not applicable

Unravelling Energy Issues Underpinning Low Energy Availability in High Performance Athletes

NCT07026175 · tracked via the Priya Life Science Australia tracker
Sponsor
Australian Catholic University
Phase
Not applicable
Started
2025-09-04
Last updated
2026-08-13

Condition(s) studied

Relative Energy Deficiency in Sport

Investigational drug(s) / intervention(s)

Diet-induced low energy availabilityExercise-induced low energy availability

Diet-induced low energy availability: 6-days of severe low energy availability (LEA, 15kcal/kg FFM/d), achieved by superimposing restricted energy intake on the control trial.

Exercise-induced low energy availability: 6-days of severe low energy availability (LEA, 15kcal/kg FFM/d), achieved by superimposing increased exercise energy expenditure on the control trial.

Study summary

The goal of this clinical trial is to understand how the body responds to short-term, severe low energy availability (LEA) in healthy, weight-bearing endurance athletes aged 18-45 years old. LEA describes a mismatch between an individual's dietary energy intake and the energy cost of their commitments for training and competition. The main questions this trial aims to answer are:

1. What effect does short-term, severe LEA have on sleeping metabolic rate?
2. What effect does short-term, severe LEA have on other body systems identified within the Relative Energy Deficiency in Sport (REDs) Health and Performance Conceptual models?

Researchers will compare a control trial with both a LEA trial achieved through diet restriction and a LEA trial achieved through increased exercise to see if there are differences in the body's response.

Participants will complete three 6-day trials, a minimum of 3-weeks apart, involving:

* Prescribed diet (all food provided)
* Prescribed running and/or cycling exercise
* Two visits to ACU Fitzroy campus for blood tests and exercise testing
* 50 hour stay (two nights and two days) in the ACU metabolic chamber

Eligibility

Sex
ALL
Min age
18 Years
Max age
45 Years
Healthy volunteers
Accepted
Inclusion Criteria: * 18-45 years old * Well trained weight-bearing athlete (tier 2-4 1) * Perform \~45km per week of weight-bearing endurance training, and able to undertake the prescribed exercise in each trial condition * Pass the ESSA pre-exercise screening tool and/or obtain GP clearance to exercise Exclusion Criteria: * Assessment of red status on the REDs Clinical Assessment Tool * Unable to attend ACU in Fitzroy, Victoria, for the 6 study visits for completion of the study protocol * Pregnancy * Use of hormonal contraceptive with the previous 3 months * Onset of peri/menopause

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Australian Catholic University Fitzroy Victoria Recruiting

More Australian Catholic University trials in Australia

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07026175 on ClinicalTrials.gov ↗ ← All trials in Australia